Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Clyde Launches New Contractility Service – CellOPTIQ®-X

Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering: Early detection of contractility toxicities Higher throughput, cost-effective solution Reduction in…

Enterprise Therapeutics Appoints Dr. John Ford as CEO

Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has appointed Dr. John Ford as CEO with immediate effect. Enterprise Therapeutics is…

EM Imaging Win Best Emerging Medtech Company Award

Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company Award. EM Imaging CEO Ian Wilson celebrates wining the Best Emerging Medtech Company Award at OBN 2016. The Awards, which…

Epidarex Capital Creates Nodthera Limited

A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, July 28, 2016:  Epidarex Capital today announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3…

Mironid Announces Closing of £4.3 million Series A Financing

Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding round of £4.3 million ($6.2 million), which will support the Company’s internal research and preclinical development programmes, focused on degenerative…